Clinic Roundup

• Curis Inc., of Lexington, Mass., said data from an investigator-sponsored trial demonstrating Erivedge's (vismodegib) proof-of-concept efficacy in treating basal cell nevus syndrome and surgically eligible basal cell carcinoma (BCC) were published in the current edition of The New England Journal of Medicine, along with a separate article reporting the results of a pivotal Phase II trial in advanced BCC.